interferon tiloron inductor usage in complex therapy at patients with community-acquired pneumonia

Clicks: 208
ID: 148295
2009
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #56 of 121 articles by views in respirology (carlton, vic)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 121 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The article presents the research findings concerning the importance of changes of the contents in blood serum of interferon gamma (INF-γ), interferon alfa (INF-α), the tumor necrosis factor alfa (TNF-α), interleukin 4 (IL-4), interleukin8 (IL-8) and clinical parameters at patients with community-acquired pneumonia before the end of treatment (basic therapy and with immunomodulator tiloron). Tiloron positive influence on clinical manifestations and immunological parameters (profile of cytokines– IL-4, IL-8, INF-α, INF-γ and INF-α) has been detected in patients with slightly complicated community-acquired pneumonia in 95 % of cases.
Reference Key
zakharova2009saratovskijinterferon Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;N.B. Zakharova;G.N. Shemetova;O.A. Kiseleva
Journal respirology (carlton, vic)
Year 2009
DOI
DOI not found
URL
http://www.ssmj.ru/system/files/200902_187_190.pdf
Keywords
cytokine profile community acquired pneumonia

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.